Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Drug Recalls For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… VIREAD (tenofovir disoproxil fumarate) Tablets, 300 mg, Gilead Sciences, Inc NDA 21-356/S5 10/14/03 10/16/03 10/16/03 VIREAD (tenofovir disoproxil fumarate) Tablets, 300 mg, Gilead Sciences, Inc NDA 21-356/S3 8/15/03 8/28/03 8/28/03 VIREAD (tenofovir disoproxil fumarate) Tablets, 300 mg, Gilead Sciences, Inc NDA 21-356/S1 12/2/02 12/9/02 12/2/02 VIREAD (tenofovir disoproxil fumarate) Tablets, 300 mg Gilead Sciences, Inc NDA 21-356 10/26/01 11/2/01 11/2/01 1/14/02 VIREAD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. VIREAD (tenofovir disoproxil fumerate) 300 mg Tablets, Gilead Sciences, Inc., Labeling Revision Truvada, (emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg)) tablets, Gilead Sciences, Approval | Truvada (emtricitabine/tenofovir DF) Tablets, Gilead Sciences, Labeling Revision | Viread (tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Efficacy Supplement w/Clinical Data | Truvada (emtricitabine/tenofovir DF) Tablets, Gilead Sciences, Labeling Revision | VIREAD (tenofovir disoproxil fumarate, TDF) Tablets, Gilead Sciences, Labeling Revision | TRUVADA Tablets, Gilead Sciences, Accelerated Approval | Truvada (emtricitabine/tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Labeling Revision | Viread (tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Labeling Revision | Tenofovir Disoproxil Fumarate Tablets, Matrix Labs, Tentative Approval | ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Labeling Revision | Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support| Viread (tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Efficacy Supplement with Clinical Data to Support | Viread (tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., New or Modified Indication | Lamivudine and Tenofovir Disoproxil Fumarate Tablets, Matrix Laboratories, Ltd., Tentative Approval | Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Labeling Revision | Viread (tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc., Labeling Revision ^ FDA's latest approval appears at the bottom of this list. ^   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | Pharma Company News © 2008 Betterchem.com